Literature DB >> 28100621

Recombinant Adenoviruses Displaying Matrix 2 Ectodomain Epitopes on Their Fiber Proteins as Universal Influenza Vaccines.

Xinying Tang1, Yong Yang1, Xiaoli Xia1, Chao Zhang1, Xi Yang1, Yufeng Song1, Xinyi Dai1, Min Wang2, Dongming Zhou3.   

Abstract

Influenza is a zoonotic disease that poses severe threats to public health and the global economy. Reemerging influenza pandemics highlight the demand for universal influenza vaccines. We developed a novel virus platform using extracellular domain IV of the matrix 2 protein (M2e), AdC68-F3M2e, by introducing three conserved M2e epitopes into the HI loop of the chimpanzee adenovirus (AdV) fiber protein. The M2e epitopes were expressed sufficiently on the AdV virion surface without affecting fiber trimerization. Additionally, one recombinant adenovirus, AdC68-F3M2e(H1-H5-H7), induced robust M2e-specific antibody responses in BALB/c mice after two sequential vaccinations and conferred efficient protection against homologous and heterologous influenza virus (IV) challenges. We found that the use of AdV with tandem M2e epitopes in fiber is a potential strategy for influenza prevention.IMPORTANCE Influenza epidemics and pandemics severely threaten public health. Universal influenza vaccines have increasingly attracted interest in recent years. Here, we describe a new strategy that incorporates triple M2e epitopes into the fiber protein of chimpanzee adenovirus 68. We optimized the process of inserting foreign genes into the AdC68 structural protein by one-step isothermal assembly and demonstrated that this 225-bp HI loop insertion could be well tolerated. Furthermore, two doses of adjuvant-free fiber-modified AdC68 could confer sufficient protection against homologous and heterologous influenza virus infections in mice. Our results show that AdC68-F3M2e could be pursued as a novel universal influenza vaccine.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  HI loop; M2e; adenovirus; immune responses; universal influenza vaccine

Mesh:

Substances:

Year:  2017        PMID: 28100621      PMCID: PMC5355597          DOI: 10.1128/JVI.02462-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector.

Authors:  Dongming Zhou; Xiangyang Zhou; Ang Bian; Hua Li; Heng Chen; Juliana C Small; Yan Li; Wynetta Giles-Davis; Zhiquan Xiang; Hildegund C J Ertl
Journal:  Nat Protoc       Date:  2010-10-14       Impact factor: 13.491

2.  High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity.

Authors:  Wanli Liu; Zou Peng; Zuqiang Liu; Yun Lu; Jian Ding; Ying-Hua Chen
Journal:  Vaccine       Date:  2004-12-02       Impact factor: 3.641

3.  Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design.

Authors:  Juliana Bessa; Nicole Schmitz; Heather J Hinton; Katrin Schwarz; Andrea Jegerlehner; Martin F Bachmann
Journal:  Eur J Immunol       Date:  2008-01       Impact factor: 5.532

4.  Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate.

Authors:  F D Batista; M S Neuberger
Journal:  Immunity       Date:  1998-06       Impact factor: 31.745

Review 5.  Production of adenovirus vectors and their use as a delivery system for influenza vaccines.

Authors:  Sai V Vemula; Suresh K Mittal
Journal:  Expert Opin Biol Ther       Date:  2010-10       Impact factor: 4.388

Review 6.  Toward a universal influenza virus vaccine: prospects and challenges.

Authors:  Natalie Pica; Peter Palese
Journal:  Annu Rev Med       Date:  2013       Impact factor: 13.739

7.  Trimeric glycosylphosphatidylinositol-anchored HCDR3 of broadly neutralizing antibody PG16 is a potent HIV-1 entry inhibitor.

Authors:  Lihong Liu; Weiming Wang; Lifei Yang; Huanhuan Ren; Jason T Kimata; Paul Zhou
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

8.  Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza.

Authors:  Eleanor L Ramos; Jennifer L Mitcham; Teri D Koller; Aurelio Bonavia; Dale W Usner; Ganesh Balaratnam; Paul Fredlund; Kristine M Swiderek
Journal:  J Infect Dis       Date:  2014-10-03       Impact factor: 5.226

9.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.

Authors:  Jiang Fan; Xiaoping Liang; Melanie S Horton; Helen C Perry; Michael P Citron; Gwen J Heidecker; Tong-Ming Fu; Joseph Joyce; Craig T Przysiecki; Paul M Keller; Victor M Garsky; Roxana Ionescu; Yvette Rippeon; Li Shi; Michael A Chastain; Jon H Condra; Mary-Ellen Davies; Jason Liao; Emilio A Emini; John W Shiver
Journal:  Vaccine       Date:  2004-08-13       Impact factor: 3.641

10.  Adenovirus-based vaccine with epitopes incorporated in novel fiber sites to induce protective immunity against Pseudomonas aeruginosa.

Authors:  Anurag Sharma; Anja Krause; Yaqin Xu; Biin Sung; Wendy Wu; Stefan Worgall
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

View more
  7 in total

1.  Engineered influenza virions reveal the contributions of non-hemagglutinin structural proteins to vaccine mediated protection.

Authors:  Zhaochen Luo; Alanson W Girton; Brook E Heaton; Nicholas S Heaton
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

Review 2.  Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture.

Authors:  Daniela S Rajão; Daniel R Pérez
Journal:  Front Microbiol       Date:  2018-02-06       Impact factor: 5.640

3.  Seamless assembly of recombinant adenoviral genomes from high-copy plasmids.

Authors:  Jessica J Miciak; Jason Hirshberg; Fred Bunz
Journal:  PLoS One       Date:  2018-06-27       Impact factor: 3.240

Review 4.  Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines.

Authors:  Ekramy E Sayedahmed; Ahmed Elkashif; Marwa Alhashimi; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Vaccines (Basel)       Date:  2020-10-01

Review 5.  Novel viral vectors in infectious diseases.

Authors:  Ian R Humphreys; Sarah Sebastian
Journal:  Immunology       Date:  2017-09-26       Impact factor: 7.397

6.  An Inactivated Influenza Virus Vaccine Approach to Targeting the Conserved Hemagglutinin Stalk and M2e Domains.

Authors:  Weina Sun; Allen Zheng; Robert Miller; Florian Krammer; Peter Palese
Journal:  Vaccines (Basel)       Date:  2019-09-18

7.  Immunoinformatic construction of an adenovirus-based modular vaccine platform and its application in the design of a SARS-CoV-2 vaccine.

Authors:  Pedro Soares Porto; Déborah Anjos; Nathânia Dábilla; Simone Gonçalves da Fonseca; Menira Souza
Journal:  Infect Genet Evol       Date:  2020-08-03       Impact factor: 3.342

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.